PMID- 31699358
OWN - NLM
STAT- MEDLINE
DCOM- 20200416
LR  - 20200416
IS  - 1879-1913 (Electronic)
IS  - 0002-9149 (Linking)
VI  - 125
IP  - 1
DP  - 2020 Jan 1
TI  - Meta-Analysis Comparing Torsemide Versus Furosemide in Patients With Heart 
      Failure.
PG  - 92-99
LID - S0002-9149(19)31108-7 [pii]
LID - 10.1016/j.amjcard.2019.09.039 [doi]
AB  - Although torsemide's oral bioavailability and half-life theoretically render it a 
      more efficient diuretic than furosemide, the clinical outcomes of torsemide 
      compared with furosemide remain unclear. We performed a systematic review and 
      meta-analysis, including all published studies that compared torsemide and 
      furosemide use in heart failure patients from January 1996 through August 2019. 
      Nineteen studies (9 randomized control trials [RCTs] and 10 observational 
      studies) with a total of 19,280 patients were included. During a mean follow-up 
      duration of 15 months, torsemide was associated with a numerically lower risk of 
      hospitalization due to heart failure (10.6% vs 18.4%; odds ratio [OR] 0.72, 95% 
      confidence interval [CI] [0.51, 1.03], p = 0.07, I(2) = 18%; number needed to 
      treat [NNT] = 23) compared with furosemide. Torsemide was associated with 
      statistically significant more improvement in functional status from New York 
      Heart Association (NYHA) class III/IV to I/II (72.5% vs 58%; OR 2.32, 95% CI 
      (1.32, 4.1), p = 0.004, I(2) = 27%; NNT = 5) and lower risk of cardiac mortality 
      (1.5% vs 4.4%; OR 0.37, 95% CI (0.20, 0.66), p <0.001, I(2) = 0%, NNT = 40) 
      compared with furosemide. However, there was no difference in all-cause mortality 
      or medication side effects between the 2 groups. In conclusion, compared with 
      furosemide, torsemide use was associated with significant more improvement in 
      functional status and lower cardiac mortality; and numerically fewer 
      hospitalizations in patients with heart failure.
CI  - Copyright (c) 2019 Elsevier Inc. All rights reserved.
FAU - Abraham, Bishoy
AU  - Abraham B
AD  - Department of Medicine, Ascension Saint John Hospital, Detroit, Michigan. 
      Electronic address: bisho.abraham@gmail.com.
FAU - Megaly, Michael
AU  - Megaly M
AD  - Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, 
      Minnesota; Division of Cardiovascular Medicine, Department of Medicine, Hennepin 
      Healthcare, Minneapolis, Minnesota.
FAU - Sous, Mina
AU  - Sous M
AD  - Department of Internal Medicine, Amita Health Saint Francis Hospital, Evanston, 
      Illinois.
FAU - Fransawyalkomos, Mina
AU  - Fransawyalkomos M
AD  - Department of Internal Medicine, Saint Joseph University Medical Center, 
      Paterson, New Jersey.
FAU - Saad, Marwan
AU  - Saad M
AD  - Department of Cardiovascular Medicine, University of Arkansas for 
      MedicalSciences, Little Rock, Arkansas; Department of Cardiology, Ain Shams 
      University Hospitals, Cairo, Egypt.
FAU - Fraser, Robert
AU  - Fraser R
AD  - Minneapolis Heart Institute, Abbott Northwestern Hospital, Minneapolis, 
      Minnesota; Division of Cardiovascular Medicine, Department of Medicine, Hennepin 
      Healthcare, Minneapolis, Minnesota.
FAU - Topf, Joel
AU  - Topf J
AD  - Division of Nephrology, Department of Medicine, Ascension Saint John Hospital, 
      Detroit, Michigan.
FAU - Goldsmith, Steven
AU  - Goldsmith S
AD  - Division of Cardiovascular Medicine, Department of Medicine, Hennepin Healthcare, 
      Minneapolis, Minnesota.
FAU - Simegn, Mengistu
AU  - Simegn M
AD  - Division of Cardiovascular Medicine, Department of Medicine, Hennepin Healthcare, 
      Minneapolis, Minnesota.
FAU - Bart, Bradley
AU  - Bart B
AD  - Division of Cardiovascular Medicine, Department of Medicine, Minneapolis VA 
      Medical Center, Minneapolis, Minnesota.
FAU - Azzo, Zain
AU  - Azzo Z
AD  - Division of Cardiology, Department of Medicine, Ascension Saint John Hospital, 
      Detroit, Michigan.
FAU - Mesiha, Nancy
AU  - Mesiha N
AD  - Division of Cardiology, Department of Medicine, Ascension Saint John Hospital, 
      Detroit, Michigan.
FAU - Sharma, Rajaninder
AU  - Sharma R
AD  - Department of Medicine, Ascension Saint John Hospital, Detroit, Michigan.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20191010
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Sodium Potassium Chloride Symporter Inhibitors)
RN  - 7LXU5N7ZO5 (Furosemide)
RN  - W31X2H97FB (Torsemide)
SB  - IM
CIN - Am J Cardiol. 2020 Apr 15;125(8):1285. PMID: 32098657
CIN - Am J Cardiol. 2020 Jul 15;127:200. PMID: 32456832
MH  - Furosemide/*therapeutic use
MH  - Heart Failure/*drug therapy/physiopathology
MH  - Humans
MH  - Sodium Potassium Chloride Symporter Inhibitors/therapeutic use
MH  - Stroke Volume/drug effects/*physiology
MH  - Torsemide/*therapeutic use
MH  - Treatment Outcome
EDAT- 2019/11/09 06:00
MHDA- 2020/04/17 06:00
CRDT- 2019/11/09 06:00
PHST- 2019/07/19 00:00 [received]
PHST- 2019/09/25 00:00 [revised]
PHST- 2019/09/27 00:00 [accepted]
PHST- 2019/11/09 06:00 [pubmed]
PHST- 2020/04/17 06:00 [medline]
PHST- 2019/11/09 06:00 [entrez]
AID - S0002-9149(19)31108-7 [pii]
AID - 10.1016/j.amjcard.2019.09.039 [doi]
PST - ppublish
SO  - Am J Cardiol. 2020 Jan 1;125(1):92-99. doi: 10.1016/j.amjcard.2019.09.039. Epub 
      2019 Oct 10.